Nanobiotix (NBTX) Competitors

$34.77 +3.61 (+11.59%)

Closing price 04:00 PM Eastern

Extended Trading

$34.38 -0.40 (-1.14%)

As of 04:10 PM Eastern

NBTX vs. PTGX, BLTE, COGT, TERN, and APGE

Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Protagonist Therapeutics (PTGX), Belite Bio (BLTE), Cogent Biosciences (COGT), Terns Pharmaceuticals (TERN), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does Nanobiotix compare to Protagonist Therapeutics?

Nanobiotix (NASDAQ:NBTX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

: In the previous week, Protagonist Therapeutics had 11 more articles in the media than Nanobiotix. MarketBeat recorded 14 mentions for Protagonist Therapeutics and 3 mentions for Nanobiotix. Protagonist Therapeutics' average media sentiment score of 1.22 beat Nanobiotix's score of 0.75 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
7 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Nanobiotix has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
: Nanobiotix has higher earnings, but lower revenue than Protagonist Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nanobiotix $36.87M 45.76 -$27.11M N/A N/A
Protagonist Therapeutics $46.02M 138.64 -$130.15M -$2.05 N/A
: Nanobiotix currently has a consensus target price of $26.67, indicating a potential downside of 23.31%. Protagonist Therapeutics has a consensus target price of $108.15, indicating a potential upside of 9.02%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Nanobiotix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
Protagonist Therapeutics
1 Sell rating(s)

1 Hold rating(s)

13 Buy rating(s)

0 Strong Buy rating(s)
2.80
: Nanobiotix has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -282.83%. Nanobiotix's return on equity of 0.00% beat Protagonist Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Nanobiotix N/A N/A N/A
Protagonist Therapeutics -282.83% -19.89% -18.40%
: 38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$36.87M	45.76	-$27.11M	N/A	N/A
Protagonist Therapeutics	$46.02M	138.64	-$130.15M	-$2.05	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Protagonist Therapeutics	-282.83%	-19.89%	-18.40%

Summary

Protagonist Therapeutics beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

: Nanobiotix's return on equity of 0.00% beat Belite Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Belite Bio N/A -19.49% -19.05%
Nanobiotix N/A N/A N/A
: Belite Bio currently has a consensus target price of $202.33, indicating a potential upside of 31.06%. Nanobiotix has a consensus target price of $26.67, indicating a potential downside of 23.31%. Given Belite Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Belite Bio is more favorable than Nanobiotix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Belite Bio
1 Sell rating(s)
1 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.63
Nanobiotix
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Belite Bio had 7 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Belite Bio and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.75 beat Belite Bio's score of 0.26 indicating that Nanobiotix is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Belite Bio
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Belite Bio has a beta of -1.19, meaning that its stock price is 219% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
: 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Nanobiotix has higher revenue and earnings than Belite Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Belite Bio N/A N/A -$77.61M -$2.30 N/A
Nanobiotix $36.87M 45.76 -$27.11M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Nanobiotix	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Nanobiotix	$36.87M	45.76	-$27.11M	N/A	N/A

Summary

Nanobiotix beats Belite Bio on 7 of the 12 factors compared between the two stocks.

How does Nanobiotix compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

: Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Cogent Biosciences N/A -143.09% -66.96%
Nanobiotix N/A N/A N/A
: Cogent Biosciences currently has a consensus target price of $43.45, indicating a potential upside of 17.54%. Nanobiotix has a consensus target price of $26.67, indicating a potential downside of 23.31%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cogent Biosciences is more favorable than Nanobiotix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogent Biosciences
1 Sell rating(s)
2 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.86
Nanobiotix
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, Cogent Biosciences had 5 more articles in the media than Nanobiotix. MarketBeat recorded 8 mentions for Cogent Biosciences and 3 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 1.10 beat Nanobiotix's score of 0.75 indicating that Cogent Biosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cogent Biosciences
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Cogent Biosciences has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
: 38.8% of Nanobiotix shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Nanobiotix has higher revenue and earnings than Cogent Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A
Nanobiotix $36.87M 45.76 -$27.11M N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-143.09%	-66.96%
Nanobiotix	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Nanobiotix	$36.87M	45.76	-$27.11M	N/A	N/A

Summary

Cogent Biosciences beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Terns Pharmaceuticals?

Terns Pharmaceuticals (NASDAQ:TERN) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

: Terns Pharmaceuticals has a beta of -0.37, meaning that its share price is 137% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
: Nanobiotix's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Terns Pharmaceuticals N/A -20.02% -19.37%
Nanobiotix N/A N/A N/A
: In the previous week, Terns Pharmaceuticals had 3 more articles in the media than Nanobiotix. MarketBeat recorded 6 mentions for Terns Pharmaceuticals and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.75 beat Terns Pharmaceuticals' score of 0.66 indicating that Nanobiotix is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Terns Pharmaceuticals presently has a consensus target price of $55.14, indicating a potential upside of 4.13%. Nanobiotix has a consensus target price of $26.67, indicating a potential downside of 23.31%. Given Terns Pharmaceuticals' higher possible upside, research analysts clearly believe Terns Pharmaceuticals is more favorable than Nanobiotix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
1 Sell rating(s)
10 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.27
Nanobiotix
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Nanobiotix has higher revenue and earnings than Terns Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Terns Pharmaceuticals N/A N/A -$96.21M -$1.03 N/A
Nanobiotix $36.87M 45.76 -$27.11M N/A N/A
: 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Terns Pharmaceuticals	N/A	-20.02%	-19.37%
Nanobiotix	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Terns Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Terns Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Terns Pharmaceuticals	N/A	N/A	-$96.21M	-$1.03	N/A
Nanobiotix	$36.87M	45.76	-$27.11M	N/A	N/A

Summary

Nanobiotix beats Terns Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

: Apogee Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
: Nanobiotix's return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Apogee Therapeutics N/A -36.77% -34.87%
Nanobiotix N/A N/A N/A
: In the previous week, Apogee Therapeutics had 4 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Apogee Therapeutics and 3 mentions for Nanobiotix. Apogee Therapeutics' average media sentiment score of 0.90 beat Nanobiotix's score of 0.75 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apogee Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nanobiotix
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Apogee Therapeutics presently has a consensus target price of $112.73, indicating a potential upside of 35.35%. Nanobiotix has a consensus target price of $26.67, indicating a potential downside of 23.31%. Given Apogee Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Apogee Therapeutics is more favorable than Nanobiotix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apogee Therapeutics
1 Sell rating(s)
4 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
2.78
Nanobiotix
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Nanobiotix has higher revenue and earnings than Apogee Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apogee Therapeutics N/A N/A -$255.84M -$4.22 N/A
Nanobiotix $36.87M 45.76 -$27.11M N/A N/A
: 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-36.77%	-34.87%
Nanobiotix	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.22	N/A
Nanobiotix	$36.87M	45.76	-$27.11M	N/A	N/A

Summary

Apogee Therapeutics beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.09B	$6.25B	$11.77B
Dividend Yield	N/A	1.92%	2.74%	5.26%
P/E Ratio	N/A	18.37	29.25	27.07
Price / Sales	45.76	278.28	504.68	73.43
Price / Cash	N/A	55.25	43.30	53.90
Price / Book	-17.65	4.30	9.67	6.69
Net Income	-$27.11M	$72.19M	$3.55B	$332.64M
7 Day Performance	4.98%	2.03%	1.70%	2.01%
1 Month Performance	12.02%	6.42%	5.62%	9.19%
1 Year Performance	872.86%	37.74%	34.42%	39.59%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.7176 of 5 stars	$34.77 +11.6%	$26.67 -23.3%	N/A	$1.51B	$36.87M	N/A	100	News Coverage Gap Up
PTGX Protagonist Therapeutics	1.7015 of 5 stars	$98.74 +0.2%	$108.15 +9.5%	N/A	$6.29B	$46.02M	N/A	120	News Coverage Positive News Earnings Report
BLTE Belite Bio	2.9318 of 5 stars	$157.04 -3.7%	$202.33 +28.8%	N/A	$6.28B	N/A	N/A	10	Upcoming Earnings Insider Trade
COGT Cogent Biosciences	2.8838 of 5 stars	$36.69 +0.2%	$43.45 +18.5%	N/A	$6.27B	N/A	N/A	80	News Coverage Positive News Earnings Report
TERN Terns Pharmaceuticals	1.1384 of 5 stars	$52.97 +0.0%	$55.14 +4.1%	N/A	$6.11B	N/A	N/A	40	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. PTGX, BLTE, COGT, TERN, and APGE

How does Nanobiotix compare to Protagonist Therapeutics?

Summary

How does Nanobiotix compare to Belite Bio?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to Terns Pharmaceuticals?

Summary

How does Nanobiotix compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. PTGX, BLTE, COGT, TERN, and APGE

How does Nanobiotix compare to Protagonist Therapeutics?

Summary

How does Nanobiotix compare to Belite Bio?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to Terns Pharmaceuticals?

Summary

How does Nanobiotix compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools